Special collections

1483 Activity of IDP-023 allogeneic g-NK cells without antibody targeting in first-in-human phase 1/2 study in patients with advanced multiple myeloma or non-hodgkin lymphoma
Krina Patel, Mitul Gandhi, Neil Sankar, Austin B Bigley, Matthew R Collinson-Pautz, Shanae Spade, Jenna Recker, Chris Gracia, Guy Dipierro, Stefanie J Mandl-Cashman, Mark Frohlich, Amiee Merino

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1713; DOI: 10.1136/jitc-2024-SITC2024.1483
1484 T cell receptor sequence clustering correlates with response to combination immunotherapy in fibrolamellar carcinoma
Allison M Kirk, Marina Baretti, Samir Adhikari, Balaji Sundararaman, Zeal Kamdar, Kayla J Bendinelli, Jeremy Chase C Crawford, Mikhail V Pogorelyy, Mark Yarchoan, Paul G Thomas

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1714; DOI: 10.1136/jitc-2024-SITC2024.1484
1485 Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis
Yinghong Wang, Krishnavathana Varatharajalu, Malek Shatila, Carolina Colli Cruz, Matthew T Campbell, Rodabe N Amaria, Anusha Shirwaikar Thomas

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1715; DOI: 10.1136/jitc-2024-SITC2024.1485
1486 Preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus cemiplimab in advanced non-small cell lung cancer after progression on PD-1 inhibition
Akin Atmaca, Jürgen Alt, David Vicente Baz, Rafal Dziadziuszko, Victor Moreno, Varela Pose, Oscar Juan-Vidal, Neru Munshi, Janet L Markman, Victoria Chen, Manas Kumar Rout, Chiara Dalle Fratte, Chris D Hermann, Tobias Burkard, Iryna Tsyhankova, Michael Wenger, Israel Lowy, Frank Seebach, Patrick Brück, Özlem Türeci, Ugur Sahin

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1716; DOI: 10.1136/jitc-2024-SITC2024.1486
1487 Results from a phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer
Jeffrey M Clarke, Ryan Gentzler, Lin Gu, Alberto Chiappori, Frank Weinberg, Gregory Durm, Sarada Gurubhagavatula, Thomas Stinchcombe, James Herndon, Hirva Mamdani

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1717; DOI: 10.1136/jitc-2024-SITC2024.1487
1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results
Benjamin C Creelan, Kai He, Edward Garon, Jason Chesney, Sylvia Lee, Jorge Nieva, Adrian Sacher, Friedrich Graf Finckenstein, Brian Gastman, Jeffrey Chou, Rana Fiaz, Melissa Catlett, Guang Chen, Adam Schoenfeld

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1718; DOI: 10.1136/jitc-2024-SITC2024.1488
1489 REStoring lymphoCytes using NKTR-255 after chemoradiothErapy in solid tumors (RESCUE): preplanned interim safety and efficacy analysis
Steven H Lin, Ying-Shiuan Chen, Priti Gupta, Madison Kahanek, Rebecca S Tidwell, Hyunsoo Hwang, Peter F Thall, Stephen G Chun, Joe Y Chang, Zhongxing Liao, Zachary Lee, Mario A Marcondes, Mary Tagliaferri, George R Blumenschein, Janet Tu, John V Heymach, Mehmet Altan

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1719; DOI: 10.1136/jitc-2024-SITC2024.1489
1491 Phase 2 study of pembrolizumab (pemb) plus plinabulin (plin) and docetaxel (doc) for NSCLC patients (pts) after failure on immune checkpoint inhibitor therapy: initial efficacy and safety results
Yan Xu, Xiaoxing Gao, Minjiang Chen, Xiaoyan Liu, Jing Zhao, Wei Zhong, Mengzhao Wang

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1720; DOI: 10.1136/jitc-2024-SITC2024.1491
1492 Telomere-targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic benefits beyond treatment cessation – A phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients
Csoszi Tibor, Tomasz Jankowski, Laszlo Urban, Tunde Nagy, Nataliya Chilingirova, Maria Cholakova, Rohit Joshi, Melissa Moore, Rodryg Ramlau, Szabolcs Soter, Marek Kotlarski, Krassimir Koynov, Andrzej Mruk, Brenton Seidl, Velko Minchev, Veronika Muller, Vlad Vitoc, Sergei Gryaznov, Matthew Failor, Oleg Tudos, Ilgen Mender, Romina Girotti, Marcel Mitsunaga, Peter Kim, Victor Zaporojan

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1721; DOI: 10.1136/jitc-2024-SITC2024.1492
1493 The armoured T-cell antigen coupler receptor (TAC) T cells with the integrated CD28 signaling, TAC28-T
Cheng Wei, Tianlong Xu, Deming Duan, Yue Gao, Ai Zhao, Jinhong Jiang, Binmu Fang, Jimin Gao

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 3) A1722; DOI: 10.1136/jitc-2024-SITC2024.1493

Main menu

Special collections

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Special collections

Pages